Liver metastatic patients with NSCLC that had been treated with anti-PD-1 antibody monotherapy were associated with reduced responses and progression-free survival, and the liver metastases were associated with reduced marginal CD8+ T cell infiltration [29]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.